ESTEVE Reports 5% Revenue Growth and Strengthens Strategy for Specialized Pharma Sector

ESTEVE's Growth Journey: A 5% Revenue Increase

In a significant year for ESTEVE, the Spanish pharmaceutical company reported a net revenue of €744 million for 2024, marking a noteworthy 5% increase from the previous year. This upward trend not only exemplifies the company’s robust growth trajectory but also reaffirms its ongoing transition into an internationally recognized specialized healthcare provider.

Detailed Performance Overview

The latest annual report highlights a strategic emphasis on international markets, as evidenced by the fact that approximately 75% of the total revenues are derived from sales abroad. Of this revenue, 25% originated from Spain, while the remaining revenues were distributed across other European Union countries (53%) and the rest of the world (22%). This impressive share of international sales underlines ESTEVE’s successful global strategy.

Key Contributions to Growth

A significant driver of ESTEVE’s net revenue growth is attributed to its pharmaceutical segment, which recorded growth exceeding 15% in net revenues. Furthermore, the CDMO (Contract Development and Manufacturing Organization) sector contributed positively with stable revenues, bolstered by a more value-added product mix. The acquisition of HRA Pharma Rare Diseases in July 2024 played a key role in enhancing ESTEVE’s portfolio, adding three new therapies addressing conditions like Cushing's syndrome and adrenal carcinoma.

Innovations and Future Strategies

Looking ahead, ESTEVE continues to push for specialized therapies, evident in its recent agreement to acquire an adjunct treatment recognized as a standard for highly resectable, non-metastatic osteosarcomas, with completion anticipated soon. In parallel, the company finalized the licensing of a biological product aimed at children and adolescents aged 2 to 18 suffering from severe primary insulin-like growth factor 1 (IGF-1) deficiency.

According to staffan Schüberg, CEO of ESTEVE, the previous year’s performance is “not just a consolidation of our growth trajectory over the past four years but also a reflection of our commitment to enhancing quality of life through specialized solutions.” He emphasized optimism for 2025, forecasting it to be a pivotal year for ESTEVE’s ascent as a leading player in specialized medicine.

Commitment to Innovation

Innovation continues to be a fundamental pillar of ESTEVE’s strategy, with an investment of €46 million in research and development in both product and process development—accounting for over 6% of the global net revenue. This commitment is further exemplified by ESTEVE’s efforts to bolster its manufacturing capabilities around the globe, including the initiation of a new facility to consolidate its operations currently based in China and a new pharmaceutical active ingredient plant in Celrà, Spain.

Social Impact and Sustainability Initiatives

The humanitarian impact of ESTEVE's treatments reached 8 million patients in 2024 across various medical fields, including endocrinology, oncology, and pain management. Notably, the company has also allocated over €1.3 million toward sustainability, diversity, and inclusion initiatives, achieving a workforce increase of 6.6% and gender parity in management roles, with women occupying 50% of leadership positions.

As a part of its continued commitment to sustainability, ESTEVE aims to achieve net-zero emissions by 2050. In the past year, the company has sourced 100% of its purchased electricity from renewable sources. Additionally, they have successfully reduced their carbon footprint by 5.8% compared to 2023, and by 10.41% compared to 2022, along with lowering water consumption by 12% in the same period.

About ESTEVE

Founded in 1929 and headquartered in Barcelona, ESTEVE is a global pharmaceutical company with a clear goal of enhancing lives. It holds a substantial international presence with operations in Spain, Portugal, Italy, Germany, France, the United Kingdom, and the USA, focusing on specialized treatments addressing significant unmet medical needs. The company also provides comprehensive manufacturing services, specializing in pharmaceutical active ingredients in top-tier facilities across Spain, Mexico, and China.

For more information, please contact Gemma Mestre at ESTEVE, +34 93 446 60 00, or via email at [email protected] or alternatively, reach out to LLYC at +34 93 217 22 17, [email protected]